m2p-labs on Course for Growth
Complete the form below to unlock access to ALL audio articles.
m2p-labs reaches break-even point, thanks to a strong demand for technology in 2010. Strengthened by good sales figures, long-standing investors are now investing in the company’s growth: the Seed Fund for the Region of Aachen GmbH & Co. KG, the KfW with the ERP Start-Up Fund and the High-Tech-Gründerfonds (business start-up fund), as well as two private investors.
m2p-labs is a leading provider of innovative screening and fermentation technologies for the pharmaceutical, biotechnical and chemical industries. Its’ product portfolio is subdivided into analysis systems, consumables, automation and culture media.
The products, with high throughput and an abundance of online process information, enable the user to accelerate F&E processes significantly.
The considerable expansion of the sales and service team is a central focus of capital increase. Several experienced sales representatives will be employed in the second half of 2011 to promote direct contact with the customer in order to fulfil the customer’s needs more specifically. The number of employees in the company is expected to grow to 11 by the end of 2011.
Due to the company‘s maturation to an established technology supplier for the chemical and pharmaceutical industry, as well as the increase in employees, m2p-labs is also increasing in space. The biotechnological company is underlining this with a move from Aachen to Baesweiler to the International Technology and Service Centre (ITS).
“In the ITS we have 350 square metres at our disposal, more than three times the surface area we had before”, Dr. Frank Kensy, managing director of m2p-labs GmbH, now rejoices. A new microtiter plate production and the quality control of instrument production are to be built on the new premises. As well as this there are three laboratories available for microbial and cell cultivation.
“We will use the fresh capital, not only for sales expansion, but also to promote the technological development of new promising products and to invest in their launch onto the market”, emphasizes Carsten Müller, managing partner of m2p-labs. The continued development of the BioLector technology for the bioeconomy plays a central role here.
“The change of feedstocks in the chemical industry from oil to renewable raw materials requires the use of more biotechnological process steps for the material conversion into new chemical entities”, according to Dr. Frank Kensy.
Kensy continued, “Innovative technology, such as the BioLector which m2p-labs offers, is necessary for this.” The BioLector allows the online monitoring of cell growth and product formation of new strains already at micro-scale under standardized conditions. In this manner, valuable process information can be gained in high throughput and can make an important contribution to the knowledge-based bioeconomy.
